Pathogenesis of the hantavirus pulmonary syndrome

Future Virology

Volumn 7, Issue 1, 2012, Pages 41-51

  Koster, Frederick ^a   MacKow, Erich ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Andes virus; hamster; hantavirus; hantavirus pulmonary syndrome; integrins; pathogenesis; pulmonary edema; Sin Nombre virus; vascular leak syndrome; VEGF

Indexed keywords

HLA ANTIGEN; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ALLELE; ASSISTED VENTILATION; BACKACHE; BLOOD CLOTTING DISORDER; BLOOD VESSEL PERMEABILITY; CAPILLARY LEAK SYNDROME; CD8+ T LYMPHOCYTE; CHILL; COUGHING; DYSPNEA; ENCEPHALITIS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXTRACORPOREAL OXYGENATION; FEVER; HANTAVIRUS PULMONARY SYNDROME; HEADACHE; HUMAN; HYPOXEMIA; IMMUNOPATHOGENESIS; INCUBATION TIME; INTERSTITIAL PNEUMONIA; LIFE CYCLE; LUNG EDEMA; LUNG INFILTRATE; MYALGIA; NONHUMAN; OXYGEN THERAPY; PATHOPHYSIOLOGY; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; SHOCK; TACHYCARDIA; TACHYPNEA; THROMBOCYTOPENIA; UMBILICAL VEIN ENDOTHELIAL CELL; VIREMIA; VIRUS PATHOGENESIS; VOMITING;

ANDES VIRUS; CRICETINAE; HANTAVIRUS; SIN NOMBRE VIRUS;

EID: 84555218337     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.138     Document Type: Review

References (116)

1. Hjelle B, Torres-Perez F. Hantaviruses in the Americas and their role as emerging pathogens. Viruses 2, 2559-2586 (2011).
2. Fulhorst CF, Koster FT, Enria DA, Peters CJ. Hantavirus infections. In: Tropical Infectious Diseases: Principles, Pathogens, and Practice. Guerrant RL, Walker DH, Weller PF (Eds). Saunders-Elsevier, PA, USA, 470-482 (2011).
3. Johnson KM. Hantaviruses: history and overview. Curr. Top. Microbiol. Immunol. 256, 1-14 (2001). (Pubitemid 32016370)
4. Schmaljohn CS, Nichol ST. Bunyaviridae: the viruses and their replication. In: Fields Virology (2nd Edition). Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 1742-1789 (2007).
5. Mertz GJ, Hjelle B, Crowley MR, Iwamoto G, Tomicic V, Vial CP. Diagnosis and treatment of new world hantavirus infections. Curr. Opin. Infect. Dis. 19, 437-442 (2006). (Pubitemid 44338102)
6. Khaiboullina SF, Morzunov S, St Jeor SC. Hantaviruses: molecular biology, evolution and pathogenesis. Curr. Mol. Med. 5, 773-790 (2005). (Pubitemid 43009517)
7. Mackow ER, Gavrilovskaya IN. Hantavirus regulation of endothelial cell functions. Thromb. Haemostat. 102, 1030-1041 (2009).
8. Terajima M, Ennis FA. T cells and pathogenesis of hantavirus cardiopulmonary syndrome and hemorrhagic fever with renal syndrome. Viruses 3, 1059-1073 (2011).
9. Nichol ST, Spiropoulou CF, Morzunov S et al. Genetic identifcation of a novel hantavirus associated with an outbreak of acute respiratory illness in the southwestern United States. Science 262, 914-917 (1993). (Pubitemid 24014083)
10. Duchin JS, Koster FT, Peters CJ et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. N. Engl. J. Med. 330(14), 949-955 (1994). (Pubitemid 24103592)
11. Koster F, Foucar K, Hjelle B et al. Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review. Am. J. Clin. Pathol. 116, 665-672 (2001). (Pubitemid 34453206)
12. Hjelle B, Jenison S, Torrez-Martinez N et al. Rapid and specifc detection of Sin Nombre virus antibodies in patients with hantavirus pulmonary syndrome by a strip immunoblot assay suitable for feld diagnosis. J. Clin. Microbiol. 35(3), 600-608 (1997). (Pubitemid 27083846)
13. Zavasky DM, Hjelle B, Peterson MC, Denton, RW, Reimer L. Acute infection with Sin Nombre hantavirus without pulmonary edema. Clin. Infect. Dis. 29, 664-666 (1999). (Pubitemid 29439968)
14. Armien B, Pascale JM, Bayard V et al. High seroprevalence of hantavirus infection on the Azuero peninsula of Panama. Am. J. Trop. Med. Hyg. 70(6), 682-687 (2004). (Pubitemid 38802402)
15. Armien B, Pascale JM, Munoz C et al. Incidence rate for hantavirus infections without pulmonary syndrome, Panama. Emerg. Infect. Dis. 17(10), 1936-1939 (2011).
16. Ferrer JF, Jonsson CB, Esteban E et al. High prevalence of hantavirus infection in Indian communities of the Paraguayan and Argentinean Gran Chaco. Am. J. Trop. Med. Hyg. 59(3), 438-444 (1998). (Pubitemid 28429088)
17. Pini N. Hantavirus pulmonary syndrome in Latin America. Curr. Opin. Infect. Dis. 17(5), 427-431 (2004). (Pubitemid 39407373)
18. Ferres M, Vial P. Hantavirus infection in children. Curr. Opin. Pediatr. 16(1), 70-75 (2004). (Pubitemid 38168164)
19. Ketai LH, Kelsey CA, Jordan K et al. Distinguishing hantavirus pulmonary syndrome from acute respiratory distress syndrome by chest radiography: are there different radiographic manifestations of increased alveolar permeability? J. Thorac. Imaging 13(3), 172-177 (1998). (Pubitemid 28339872)
20. Hallin GW, Simpson SQ, Crowell RE et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit. Care Med. 24(2), 252-258 (1996). (Pubitemid 26065332)
21. Dietl CA, Wernly JA, Pett SB et al. Extracorporeal membrane oxygenation support improves survival of patients with severe hantavirus cardiopulmonary syndrome. J. Thorac. Cardiovasc. Surg. 135, 579-584 (2008).
22. MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary syndrome, United States, 1993-2009. Emerg. Infect. Dis. 17, 1195-1201 (2011).
23. Gracia F, Armien B, Simpson SQ et al. Convalescent pulmonary dysfunction following hantavirus pulmonary syndrome in Panama and the United States. Lung 188, 387-391 (2010).
24. Huggins JW, Hsiang CM, Cosgriff TM et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164(6), 1119-1127 (1991).
25. Mertz GJ, Miedzinski L, Goade D et al. Placebo-controlled, double blind trial of intravenous ribavirin for hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 39, 1307-1313 (2004). (Pubitemid 39458516)
26. Linderholm M, Sandstrom T, Rinnstrom O et al. Impaired pulmonary function in patients with hemorrhagic fever with renal syndrome. Clin. Infect. Dis. 25(5), 1084-1089 (1997). (Pubitemid 27513191)
27. Entwisle G, Hale E. Hemodynamic alteration in hemorrhagic fever. Circulation 15, 414-425 (1957).
28. Zaki SR, Greer PW, Coffeld LM et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am. J. Pathol. 146, 552-579 (1995).
29. Green W, Feddersen R, Yousef O et al. Tissue distribution of hantavirus antigen in naturally infected humans and deer mice. J. Infect. Dis. 177(6), 1696-1700 (1998). (Pubitemid 28243597)
30. Nolte KB, Feddersen RM, Foucar K et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum. Pathol. 26, 110-120 (1995).
31. Bustamente EA, Levy H, Simpson SQ. Pleural fuid characteristics in hantavirus pulmonary syndrome. Chest 112, 1133-1136 (1997). (Pubitemid 27446346)
32. Klingstrom J, Hardestam J, Stoltz M et a l. Loss of cell membrane integrity in Puumala hantavirus-infected patients correlates with levels of epithelial cell apoptosis and perforin. J. Virol. 80, 8279-8282 (2006). (Pubitemid 44182330)
33. Lukes RJ. The pathology of thirty-nine fatal cases of epidemic hemorrhagic fever. Am. J. Med. 16, 639-650 (1954).
34. Wichmann D, Gröne HJ, Frese M et al. Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice. J. Virol. 76(17), 8890-8899 (2002). (Pubitemid 34864083)
35. Talamonti L, Padula PJ, Canteli MS, Posner F, Marczeski FP, Weller C. Hantavirus pulmonary syndrome: encephalitis caused by virus Andes. J. Neurovirol. 17(2), 189-192 (2011).
36. Groen J, Gerding MN, Koeman JP et al. A macaque model for hantavirus infection. J. Infect. Dis. 172(1), 38-44 (1995).
37. Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology 289, 6-14 (2001). (Pubitemid 33016232)
38. Milazzo ML, Eyzaguirre EJ, Molina CP, Fulhorst CF. Maporal viral infection in the Syrian golden hamster: a model of hantavirus pulmonary syndrome. J. Infect. Dis. 186, 1390-1395 (2002). (Pubitemid 35286105)
39. Hammerbeck CD, Hooper JW. T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. J. Virol. 85(19), 9929-9944 (2011).
40. Campen MJ, Milazzo ML, Fulhorst CF, Obot Akata CJ, Koster F. Characterization of shock in a hamster model of hantavirus infection. Virology 356, 45-49 (2006). (Pubitemid 44755432)
41. Wahl-Jensen V, Chapman J, Asher L et al. Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. J. Virol. 81, 7449-7462 (2007). (Pubitemid 47047833)
42. Eyzaguirre EJ, Milazzo ML, Koster FT, Fulhorst CF. Choclo virus infection in the Syrian golden hamster. Am. J. Trop. Med. Hyg. 78, 669-674 (2008). (Pubitemid 351845174)
43. Matthys VS, Gorbunova EE, Gravrilovskaya IN, Mackow ER. Andes virus recognition of human and Syrian hamster beta-integrins is determined by an L33P substitution in the PSI domain. J. Virol. 84, 352-360 (2010).
44. Medina RA, Torrez-Perez F, Galeno H et al. Ecology, genetic diversity and phylogenetic structure of Andes virus in humans and rodents in Chile. J. Virol. 83, 2446-2459 (2009).
45. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. Beta3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc. Natl Acad. Sci. USA 95(12), 7074-7079 (1998). (Pubitemid 28278109)
46. Geimonen E, LaMonica R, Springer K, Farooqui Y, Gavrilovskaya IN, Mackow ER. Hantavirus pulmonary syndrome-associated hantaviruses contain conserved and functional ITAM signaling elements. J. Virol. 77(2), 1638-1643 (2003). (Pubitemid 36055588)
47. McElroy AK, Smith JM, Hooper JW, Schmaljohn CS. Andes virus M genome segment is not suffcient to confer the virulence associated with Andes virus in Syrian hamsters. Virology 326, 130-139 (2004). (Pubitemid 38943012)
48. Raftery MJ, Kraus AA, Ulrich R, Kruger DH, Schonrich G. Hantavirus infection in dendritic cells. J. Virol. 76(21), 10724-10733 (2002).
49. Marsac D, Garcia S, Fournet A et al. Infection of human monocyte-derived dendritic cells by Andes hantavirus enhances pro-infammatory state, the secretion of active MMP-9, and indirectly enhances endothelial permeability Virol. J. 8, 223 (2011).
50. Raymond T, Gorbunova E, Gavrilovskaya IN, Mackow ER. Pathogenic hantaviruses bind plexin-semaphoring-integrin domains present at the apex of inactive, bent alpahbeta integrin conformers. Proc. Natl Acad. Sci. USA 102(4), 1163-1168 (2005). (Pubitemid 40170743)
51. Gavrilovskaya IN, Peresleni T, Geimonen E, Mackow ER. Pathogenic hantaviruses selectively inhibit beta integrin directed endothelial cell migration. Arch. Virol. 147(10), 1913-1931 (2002). (Pubitemid 35218716)
52. Rang A. Modulation of innate immune responses by hantaviruses. Crit. Rev. Immunol. 30, 515-527 (2010).
53. Ontiveros SJ, Li Q, Jonsson CB. Modulation of apoptosis and immune signaling pathways by the Hantaan virus nucleocapsid protein. Virology 401, 165-178 (2010).
54. Klingstrom J, Ahlm C. Hantavirus protein interactions regulate cellular functions and signaling responses. Expert Rev. Anti Infect. Ther. 9, 33-47 (2011).
55. Geimonen E, Neff S, Raymond T, Kocer SS, Gavrilovskaya IN, Mackow ER. Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proc. Natl Acad. Sci. USA 99, 13837-13842 (2002). (Pubitemid 35215467)
56. Kraus AA, Raftery MJ, Giese T et al. Differential antiviral response of endothelial cells after infection with pathogenic and nonpathogenic hantaviruses. J. Virol. 78, 6143-6150 (2004). (Pubitemid 38715912)
57. Shrivastava P, Rollin PE, Spiropoulou CF. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J. Virol. 84, 11227-11234 (2011).
58. Sundstrom JB, McMullan LK, Spiropoulou CF et al. Hantavirus infection induces the expression of RANTES amd IP-10 without causing increased permeability in human lung microvascular endothelial cells. J. Virol. 75, 6070-6085 (2001). (Pubitemid 32553138)
59. Khaiboullina SF, Netski DM, Krumpe P, St Jeor SC. Effects of tumor necrosis factor alpha on Sin Nombre virus infection in vitro. J. Virol. 74(24), 11966-11971 (2000). (Pubitemid 32222348)
60. Gavrilovskaya IN, Gorbunova EE, Mackow NA, Mackow ER. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability. J. Virol. 82, 5797-5806 (2008). (Pubitemid 351822254)
61. Gorbunova E, Gavrilovskaya IN, Mackow ER. Pathogenic hantaviruses Andes virus and Hantaan virus induce adherens junction disassembly by directing vascular endothelial cadherin internalization in human endothelial cells. J. Virol. 84, 7405-7411 (2010).
62. Gorbunova EE, Gavrilovskaya IN, Pepini T, Mackow ER. VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. J. Virol. 85, 2296-2303 (2011).
63. Pepini T, Gorbunova EE, Gavrilovskaya IN, Mackow JE, Mackow ER. Andes virus regulation of cellular microRNAs contributes to hantavirus-induced endothelial cell permeability. J. Virol. 84, 11929-11936 (2010).
64. Niikura M, Maeda A, Ikegami T et al. Modifcations of endothelial cell functions by Hantaan virus infection: prolonged hyper-permeability induced by TNF-alpha of Hantaan virus-infected endothelial cell monolayers. Arch. Virol. 149(7), 1279-1292 (2004). (Pubitemid 38927633)
65. Yang G, Hamacher J, Gorshkov B et al. The dual role of TNF in pulmonary edema. J. Cardiovasc. Dis. Res. 1, 29-36 (2010).
66. Linderholm M, Ahlm C, Settergren B et al. Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. J. Infect. Dis. 173, 38-43 (1996). (Pubitemid 26006801)
67. Saksida A, Wraber B, Avsic-Tupanc T. Serum levels of infammatory and regulatory cytokines in patients with hemorrhagic fever with renal syndrome. BMC Infect. Dis. 11, 142 (2011).
68. Krakauer T, Leduc J W, Krakauer H. Serum levels of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 in hemorrhagic fever with renal syndrome. Viral Immunol. 8, 75-79 (1995). (Pubitemid 26025307)
69. Mori M, Rothman AL, Kurane I et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J. Infect. Dis. 179(2), 295-302 (1999). (Pubitemid 29086629)
70. Maes P, Clement J, Groeneveld PH et al. Tumor necrosis factor-alpha genetic predisposing factors can infuence clinical severity in nephropathia epidemica. Viral Immunol. 19, 558-564 (2006). (Pubitemid 44735067)
71. Makela S, Mustonen J, Ala-Houhala I et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha(-308) G/A polymorphism. J. Infect. Dis. 186, 843-846. (2002) (Pubitemid 35013439)
72. Taylor SL, Frias-Staheli N, Garcia-Sastre A, Schmaljohn CS. Hantaan virus nucleocapsid protein binds to importin alpha proteins and inhibits tumor necrosis facdtor alpha-induced activation of nuclear factor kappa B. J. Virol. 83, 1271-1279 (2009).
73. Alff PJ, Sen N, Gorbunova E, Gavrilovskaya IN, Mackow ER. The NY-1 hantavirus Gn cytoplasmic tail coprecipitates TRAF3 and inhibits cellular interferon responses by disrupting TBK1-TRAF3 complex formation. J. Virol. 82, 9115-9122 (2008).
74. Cosgriff TM. Mechanisms of disease in Hantavirus infection: pathophysiology of hemorrhagic fever with renal syndrome. Rev. Infect. Dis. 13, 97-107 (1991).
75. Sundberg E, Hultdin J, Nilsson S, Ahlm C. Evidence of disseminated intravascular coagulation in a hemorrhagic fever with renal syndrome-scoring models and severe illness. PLoS One 6(6), E21134 (2011).
76. Van Gorp EC, Setiati TE, Mairuhu AT et al. Impaired fbrinolysis in the pathogenesis of dengue hemorrhagic fever. J. Med. Virol. 67(4), 549-554 (2002). (Pubitemid 34747676)
77. Jenison S, Yamada T, Morris C et al. Characterization of human antibody responses to four corners hantavirus infections among patients with hantavirus pulmonary syndrome. J. Virol. 68, 3000-3006 (1994). (Pubitemid 24129749)
78. Tischler ND, Galeno H, Rosenblatt M, Valenzuela PD. Human and rodent humoral immune responses to Andes virus structural proteins. Virology 334, 319-326 (2005). (Pubitemid 40386966)
79. Bharadwaj M, Nofchissey R, Goade D et al. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J. Infect. Dis. 182, 43-48 (2000). (Pubitemid 30497787)
80. Padula PJ, Colavecchia SB, Martínez VP et al. Genetic diversity, distribution, and serological features of hantavirus infection in fve countries in South America. J. Clin. Microbiol. 38, 3029-3035 (2000). (Pubitemid 30640593)
81. MacNeil A, Comer JA, Ksiazek TG, Rollin PE. Sin Nombre virus-specifc immunoglobulin M and G kinetics in hantavirus pulmonary syndrome and the role played by serologic responses in predicting disease outcome. J. Infect. Dis. 202(2), 242-246 (2010).
82. Luo DD, Wang XH, Jin WE, Fan JZ. Detection and analysis of specifc circulating immune complexes in epidemic hemorrhagic fever. Chin. J. Infect. Dis. 3, 86-90 (1985).
83. Yan DY, Gu XS, Wang DQ, Yang SH. Studies on immunopathogenesis in epidemic hemorrhagic fever: sequential observations on activation of the frst complement component in sera from patients with epidemic hemorrhagic fever. J. Immunol. 127(3), 1064-1067 (1981).
84. Jokinen EJ, Lahdevirta J, Collan Y. Nephropathia epidemica: immunohistochemical study of pathogenesis. Clin. Nephrol. 9, 1-5 (1978). (Pubitemid 8268537)
85. Huang C, Jin B, Wang M, Li E, Sun C. Hemorrhagic fever with renal syndrome: relationship between pathogenesis and cellular immunity. J. Infect. Dis. 169, 868-870 (1994). (Pubitemid 24102122)
86. + cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology 238, 380-390 (1997). (Pubitemid 28218156)
87. + T cells persist years after infection by Andes hantavirus. PLoS Pathog. 6, E1000779 (2010).
88. Terajima M, Van Epps HL, Li D et al. Generation of recombinant vaccinia viruses expressing Puumala virus proteins and use in isolating cytotoxic T cells specifc for Puumala virus. Virus Res. 84, 67-77 (2002). (Pubitemid 34251197)
89. Terajima M, Vapalahti O, Van Epps HL, Vaheri A, Ennis FA. Immune responses to Puumala virus infection and the pathogenesis of nephropathic epidemica. Microbes Infect. 6, 238-245 (2004). (Pubitemid 38293303)
90. + T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J. Immunol. 172, 3297-3304 (2004). (Pubitemid 38263722)
91. + T cells in patients with hemorrhagic fever with renal syndrome. Viral Immunol. 22, 253-260 (2009).
92. Mustonen J, Partanen J, Kanerva M et al. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. Kidney Int. 49, 217-221 (1996). (Pubitemid 26024237)
93. Mustonen J, Huttunen NP, Partanen J et al. Human leukocyte antigens B8-DRB1*03 in pediatric patients with nephropathia epidemica caused by Puumala hantavirus. Pediatr. Infect. Dis. J. 23, 959-961 (2004). (Pubitemid 40812786)
94. Koster F, Vigil J, Olson D et al. Class I, II, and III HLA alleles associated with severe hantavirus cardiopulmonary syndrome in the southwest U.S. (meeting abstract). Am. J. Trop. Med. Hyg. 65, 152 (2001).
95. Ferrer CP, Vial CPA, Ferres GM et al. Genetic susceptibility to Andes hantavirus: association between severity of disease and HLA alleles in Chilean patients. Rev. Chilena Infectol. 24, 351-359 (2007).
96. Hayasaka D, Maeda K, Ennis FA, Terajima M. Increased permeability of human endothelial cell line EA.hy926 induced by hantavirus-specifc cytotoxic T lymphocytes. Virus Res. 123, 120-127 (2007). (Pubitemid 46054332)
97. Terajima M, Hendershot JDR, Kariwa H et al. High levels of viremia in patients with the Hantavirus pulmonary syndrome. J. Infect. Dis. 180, 2030-2034 (1999).
98. Xiao R, Yang S, Koster F, Ye C, Stidley C, Hjelle B. Sin Nombre Viral RNA load in patients with the hantavirus cardiopulmonary syndrome. J. Infect. Dis. 194(10), 1403-1409 (2006). (Pubitemid 44706509)
99. 5 integrins. Nat. Med. 8, 27-34 (2002). (Pubitemid 34101725)
100. Gavrilovskaya IN, Gorbunova EE, Mackow ER. Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells. J. Virol. 84, 4832-4839 (2010).
101. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029-1039 (1995).
102. Berger MM, Hesse C, Dehnert C et al. Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. Am. J. Respir. Crit. Care Med. 172, 763-767 (2005). (Pubitemid 41324233)
103. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ. Res. 99, 675-691 (2006). (Pubitemid 44498302)
104. Tang N, Wang L, Esko J et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6, 485-495 (2004). (Pubitemid 39469984)
105. Hanaoka M, Droma Y, Naramoto A et al. Vascular endothelial growth factor in patients with high-altitude pulmonary edema. J. Appl. Physiol. 94, 1836-1840 (2003). (Pubitemid 36457433)
106. 3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler. Thromb. Vasc. Biol. 24, 2108-2114 (2004). (Pubitemid 39482438)
107. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res. 5, 487-491 (1999). (Pubitemid 29131955)
108. Zhang J, Silva T, Yarovinsky T et al. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ. Res. 107, 408-417 (2010).
109. Srikiatkhachorn A, Ajariyakhajorn C, Endy TP et al. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic fever. J. Virol. 81, 1592-1600 (2007). (Pubitemid 46214434)
110. Bodur H, Akinci E, Onguru P et al. Evidence of vascular endothelial damage in Crimean-Congo hemorrhagic fever. Int. J. Infect. Dis. 14, E704-E707 (2010).
111. Watanabi M, Boyer JL, Crystal RG. Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. Hum. Gene Ther. 20(6), 598-610 (2009).
112. Mukhopadhyay D, Tsiokas L, Zhou XM et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375, 577-581 (1995).
113. Saggioro FP, Rossi MA, Duarte MI et al. Hantavirus infection induces a typical myocarditis that may be responsible for myocardial depression and shock in hantavirus pulmonary syndrome. J. Infect. Dis. 195, 1541-1549 (2007). (Pubitemid 46717473)
114. Davis IC, Zajac AJ, Nolte KB et al. Elevated generation of reactive oxygen/nitrogen species in hantavirus cardiopulmonary syndrome. J. Virol. 76(16), 8347-8359 (2002). (Pubitemid 34809088)
115. Iqbal M, Cohen RI, Marzouk K et al. Time course of nitric oxide, peroxynitrite, and antioxidants in the endotoxemic heart. Crit. Care Med. 30, 1291-1296 (2002). (Pubitemid 34620973)
116. Safronetz D, Haddock E, Feldmann F, Ebihara H, Feldmann H. In vitro and in vivo activity of ribavirin against Andes virus infection. PLoS One 6(8), E23560 (2011).